Sim&Cure Secures €3.1M to Revolutionize Endovascular Treatments with AI and Digital Twin Technology

Sim&Cure, a pioneering digital start-up established in 2014 and embedded in the vibrant Medtech ecosystem of Montpellier, France, is thrilled to announce that it has raised €3,100,000 in its latest funding round. This significant milestone underscores the confidence investors have in Sim&Cure’s mission to enhance patient outcomes and improve physician experiences in endovascular treatments through the innovative integration of Digital Twin and AI technologies. With a philosophy deeply rooted in driving healthcare innovation and securing patient care, Sim&Cure has consistently pushed the boundaries of medical technology, helping partners navigate complex learning curves as new technologies evolve. The company’s impressive track record includes winning prestigious competitions such as the i-Lab national contest in both 2014 and 2015, and the i-Nov in 2020, demonstrating its commitment to excellence and clinical impact. Backed by the Seed Fund IT-Translation and Elaia Partners and supported by strategic scientific and clinical collaborations with leading laboratories and hospitals worldwide, Sim&Cure is well-positioned to spearhead transformative changes in treatment strategies. With a robust team of 50 professionals and a subsidiary launched in New York in July 2019, the company is now set to leverage this fresh capital to accelerate its growth phase. The funds will be dedicated to further advancing its Digital Twin and AI platform, expanding R&D efforts, and broadening its global outreach to better support its medical partners. Sim&Cure’s continued commitment to innovation and quality healthcare underscores its readiness to shape the future of endovascular treatments, ensuring that both physicians and patients benefit from groundbreaking technological advancements.